Whats new
Whats new.
Maxim - Positive Survival Data for Efti Triple Combo in 1L NSCLC; Bodes Well for Upcoming P3 Pivotal TACTI-004 Study in Same Setting - Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)
November 14th 2024
For a copy of this analyst report please contact your Maxim advisor